VRAX NASDAQ
Virax Biolabs Group Limited
1W: -8.3%
1M: -13.7%
3M: -29.3%
YTD: +472.9%
1Y: +255.2%
3Y: -29.0%
$2.20
-0.04 (-1.79%)
Weekly Expected Move ±9.1%
$2
$2
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$5M
-1.3% ▼
Capital Expenditures
$256K
+57.6% ▲
Free Cash Flow
-$5M
+5.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$2M
+245.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$2M | -$5M | -$7M | -$6M | -$5M |
| Depreciation & Amort. | $0 | $0 | $103K | $343K | $439K |
| Stock-Based Comp. | $290K | $2M | $1M | $365K | $130K |
| Change in Working Capital | $644K | -$216K | -$1M | $626K | $271K |
| Other Non-Cash Items | -$32K | -$261K | $497K | $169K | -$439K |
| Operating Cash Flow | -$809K | -$4M | -$6M | -$5M | -$5M |
| — Investing Activities — | |||||
| Capital Expenditures | $0 | -$178K | -$952K | -$604K | -$256K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $0 | -$178K | -$212K | $0 | $0 |
| Investing Cash Flow | $0 | -$178K | -$1M | -$604K | -$256K |
| — Financing Activities — | |||||
| Net Debt Issuance | $100K | $146K | -$206K | -$108K | -$109K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $194K | -$112K | $2M | $787K | $4M |
| Financing Cash Flow | $813K | $14M | $2M | $6M | $7M |
| Net Change in Cash | $4K | $9M | -$6M | $640K | $2M |
| Cash End of Period | $22K | $9M | $4M | $4M | $6M |
| Free Cash Flow | -$809K | -$4M | -$7M | -$5M | -$5M |